# Arcturus Therapeutics (ARCT) — Earnings

ARCT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/arct/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.84 |
| EPS estimate | −$0.91 |
| EPS surprise | +8.00% |
| Revenue surprise | +2.34% |
| Revenue | $3.0M |
| Revenue estimate | $2.9M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1768224/000119312526338090/arct-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/429418f9-f5a1-8822-2d6f-97aabd0efc61.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$0.91 | −$0.84 | 8.00% | $2.9M | $3.0M |
| Q1 2026 | May 7, 2026 | −$1.01 | −$0.95 | 5.93% | $6.3M | $2.1M |
| Q4 2025 | Mar 3, 2026 | −$0.78 | −$1.03 | -32.58% | $15.9M | $7.2M |
| Q3 2025 | Nov 10, 2025 | −$0.90 | −$0.49 | 45.49% | $16.0M | $17.2M |
| Q2 2025 | Aug 11, 2025 | −$0.89 | −$0.34 | 61.87% | $18.8M | $28.3M |
| Q1 2025 | May 12, 2025 | −$1.18 | −$0.52 | 55.85% | $23.4M | $29.4M |
| Q4 2024 | Mar 6, 2025 | −$0.55 | −$1.11 | -102.37% | $39.9M | $22.8M |
| Q3 2024 | Nov 7, 2024 | −$1.22 | −$0.26 | 78.62% | $36.6M | $41.7M |
| Q2 2024 | Aug 5, 2024 | −$1.50 | −$0.64 | 57.29% | $22.2M | $49.9M |
| Q1 2024 | May 8, 2024 | −$1.23 | −$1.00 | 18.94% | $17.7M | $38.0M |
| Q4 2023 | Mar 7, 2024 | −$0.99 | −$0.32 | 67.75% | $37.9M | $34.0M |
| Q3 2023 | Nov 14, 2023 | −$1.69 | −$0.61 | 63.94% | $15.9M | $45.1M |
| Q2 2023 | Aug 7, 2023 | −$0.24 | −$1.98 | -709.15% | $49.3M | $10.5M |
| Q1 2023 | May 9, 2023 | $0.06 | $1.87 | 3032.33% | $37.9M | $80.3M |
| Q4 2022 | Mar 28, 2023 | −$1.72 | $4.33 | 351.74% | $9.8M | $160.3M |
| Q3 2022 | Nov 9, 2022 | −$1.81 | −$1.33 | 26.48% | $4.6M | $13.4M |
| Q2 2022 | Aug 9, 2022 | −$1.86 | −$0.82 | 55.98% | $3.1M | $27.1M |
| Q1 2022 | May 9, 2022 | −$1.44 | −$1.94 | -34.94% | $7.1M | $5.2M |
| Q4 2021 | Feb 28, 2022 | −$1.63 | −$1.47 | 9.93% | $14.8M | $5.8M |
| Q3 2021 | Nov 8, 2021 | −$1.50 | −$2.05 | -37.01% | $21.8M | $2.4M |

## Frequently Asked Questions

### When did Arcturus Therapeutics (ARCT) last report earnings?

Arcturus Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did ARCT beat earnings estimates?

Yes. Arcturus Therapeutics reported EPS of −$0.84 for Q2 2026 against a −$0.91 estimate — a 8.00% beat.

### How much revenue did ARCT report last quarter?

Arcturus Therapeutics reported $3.0M in revenue for Q2 2026, against a consensus estimate of $2.9M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).